跳至主要内容
临床试验/NCT05671744
NCT05671744招募中不适用

Validation of a Cell-Based Technology for Non-Invasive-Prenatal-Diagnosis (CB-NIPD) Using Circulating Whole Fetal Cells From Maternal Peripheral Blood.

Menarini Biomarkers Singapore1 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2021年11月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,500
试验地点
1
主要终点
Fetal chromosomal abnormalities detection in circulating fetal cells,

研究概览

简要总结

The aim of this clinical study is the evaluation of clinical performance of a cell-based non-invasive test technology for fetal aneuploidies and segmental imbalances detection in a high-risk pregnancies population.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Participant has a viable singleton or twin pregnancy
  • Women who have already been selected by their treating physician to undergo an invasive fetal diagnostic procedure
  • Participant is at least 18 years old and can provide informed consent

排除标准

  • Unable to provide informed consent
  • Prenatal diagnosis of clinical Chorioamnionitis
  • Intake of drugs or exposure to teratogenic agents
  • Infections that carry a risk of vertical transmission
  • Known maternal viral diseases: HIV and HCV, HBV

结局指标

主要结局

Fetal chromosomal abnormalities detection in circulating fetal cells,

时间窗: 2 year

Evaluation of clinical performance of a cell-based technology for fetal chromosomal abnormalities detection in circulating fetal cells, using maternal blood samples from a population of high-risk pregnancies undergoing clinically indicated fetal diagnostic procedures.

次要结局

  • Number of suitable fetal cells(2 year)
  • Fetal sex assessment(2 year)

研究者

发起方
Menarini Biomarkers Singapore
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验